Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment

Hyperglycemia in T2DM is based on three main mechanisms: insulin resistance, progressive β-cell dysfunction, and excess glucose production by the liver.The onset of T2DM is usually preceded by a long period of insulin resistance. Prescribing sugar drugs that affect different links of pathogenesis, r...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	M. V. Shestakova, M. B. Antsiferov, A. S. Ametov, G. R. Galstyan, T. Y. Demidova, A. M. Mkrtumyan, N. A. Petunina
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2021
Materias:	diabetes mellitus alogliptin pioglitazone fixed combination Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/e11b41f30f754ce09441600dfaac4c04
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e11b41f30f754ce09441600dfaac4c04
record_format	dspace
spelling	oai:doaj.org-article:e11b41f30f754ce09441600dfaac4c042021-11-14T09:00:23ZPossibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment2072-03512072-037810.14341/DM12757https://doaj.org/article/e11b41f30f754ce09441600dfaac4c042021-07-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/12757https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Hyperglycemia in T2DM is based on three main mechanisms: insulin resistance, progressive β-cell dysfunction, and excess glucose production by the liver.The onset of T2DM is usually preceded by a long period of insulin resistance. Prescribing sugar drugs that affect different links of pathogenesis, reducing a steady decrease in glycemia. To date, in clinical practice, various combinations of hypoglycemic drugs are used, the choice of which is determined by the characteristics of the course of diabetes in the patient, the presence of concomitant diseases and complications of diabetes, as well as the dominant clinical problem. This resolution provides an expert council opinion on the feasibility of using a combination of alogliptin and pioglitazone in patients with type 2 diabetes.M. V. ShestakovaM. B. AntsiferovA. S. AmetovG. R. GalstyanT. Y. DemidovaA. M. MkrtumyanN. A. PetuninaEndocrinology Research Centrearticlediabetes mellitusalogliptinpioglitazonefixed combinationNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 24, Iss 2, Pp 193-197 (2021)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	diabetes mellitus alogliptin pioglitazone fixed combination Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	diabetes mellitus alogliptin pioglitazone fixed combination Nutritional diseases. Deficiency diseases RC620-627 M. V. Shestakova M. B. Antsiferov A. S. Ametov G. R. Galstyan T. Y. Demidova A. M. Mkrtumyan N. A. Petunina Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment
description	Hyperglycemia in T2DM is based on three main mechanisms: insulin resistance, progressive β-cell dysfunction, and excess glucose production by the liver.The onset of T2DM is usually preceded by a long period of insulin resistance. Prescribing sugar drugs that affect different links of pathogenesis, reducing a steady decrease in glycemia. To date, in clinical practice, various combinations of hypoglycemic drugs are used, the choice of which is determined by the characteristics of the course of diabetes in the patient, the presence of concomitant diseases and complications of diabetes, as well as the dominant clinical problem. This resolution provides an expert council opinion on the feasibility of using a combination of alogliptin and pioglitazone in patients with type 2 diabetes.
format	article
author	M. V. Shestakova M. B. Antsiferov A. S. Ametov G. R. Galstyan T. Y. Demidova A. M. Mkrtumyan N. A. Petunina
author_facet	M. V. Shestakova M. B. Antsiferov A. S. Ametov G. R. Galstyan T. Y. Demidova A. M. Mkrtumyan N. A. Petunina
author_sort	M. V. Shestakova
title	Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment
title_short	Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment
title_full	Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment
title_fullStr	Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment
title_full_unstemmed	Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment
title_sort	possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment
publisher	Endocrinology Research Centre
publishDate	2021
url	https://doaj.org/article/e11b41f30f754ce09441600dfaac4c04
work_keys_str_mv	AT mvshestakova possibilitiesofapplicationafixedcombinationofalogliptinandpioglitazonefortype2diabetesmellitustreatment AT mbantsiferov possibilitiesofapplicationafixedcombinationofalogliptinandpioglitazonefortype2diabetesmellitustreatment AT asametov possibilitiesofapplicationafixedcombinationofalogliptinandpioglitazonefortype2diabetesmellitustreatment AT grgalstyan possibilitiesofapplicationafixedcombinationofalogliptinandpioglitazonefortype2diabetesmellitustreatment AT tydemidova possibilitiesofapplicationafixedcombinationofalogliptinandpioglitazonefortype2diabetesmellitustreatment AT ammkrtumyan possibilitiesofapplicationafixedcombinationofalogliptinandpioglitazonefortype2diabetesmellitustreatment AT napetunina possibilitiesofapplicationafixedcombinationofalogliptinandpioglitazonefortype2diabetesmellitustreatment
_version_	1718429496885903360

Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment

Ejemplares similares